Cascara Sagrada
drugOn this page
Also known as B2340Bearberry barkCasc liqCascaraCascara buckthorn barkCascara buckthorn wholeCascara sagrada barkext.debitteredChittambarkChittem barkFEMA NO. 2253Frangula purshianaFrangula purshiana barkFrangula purshiana wholePursh's buckthorn barkPursh's buckthorn wholeRhamni purshianae cortexRhamnus purshiana bark
Summary
Cascara Sagrada (CHEMBL2108265) is an approved unknown (ATC A06AB07); indicated across 1 condition including constipation disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- ATC class: A06AB07 (+1 more)
- Indications: 1 condition
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108265 |
| Name | Cascara Sagrada |
| Type | Unknown |
| Max phase | 4 |
| ATC | A06AB07, A06AB57 |
Also known as: B2340, Bearberry bark, Casc liq, Cascara, Cascara buckthorn bark, Cascara buckthorn whole, Cascara sagrada, Cascara sagrada bark, ext., debittered, Chittambark, Chittem bark
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| constipation disorder | 4 | MONDO:0002203 | HP:0002019 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: constipation disorder